Myricetin is a flavonol polyphenol (3,3',4',5,5',7-hexahydroxyflavone) found in berries, grapes, tea, vegetables, and herbs that lacks the catechol (ortho-dihydroxy) structure on its B-ring. This structural absence is clinically critical: myricetin does NOT interact with catechol-O-methyltransferase (COMT) enzyme and therefore does not accumulate in Met/Met slow COMT genotype patients, making it a safe anti-inflammatory and antioxidant option when catechol-containing flavonoids (quercetin, EGCG, luteolin) must be avoided. It modulates inflammation via COX-2 inhibition, NF-κB suppression, and Nrf2 activation while scavenging reactive oxygen species and chelating redox-active metals.
Imagine COMT as a parking enforcement officer whose job is to tag and tow away certain illegally parked cars (catechol-containing compounds) that clog up the streets of your neurochemical neighbourhood. In people with slow COMT (Met/Met genotype), this officer works at half-speed, so catechol compounds like quercetin and EGCG pile up like a traffic jam — cars overflowing the streets, blocking fire hydrants, causing anxiety, insomnia, and digestive chaos. Myricetin is like a car that's legally parked because it doesn't have the catechol "parking violation" tag — the enforcement officer walks right past it. The car still does useful work (delivering anti-inflammatory cargo, sweeping up oxidative trash), but it never gets towed or accumulated because it was never on the violation list. This makes myricetin the perfect delivery vehicle for patients whose parking enforcement system (COMT) is too slow to handle the usual suspects. It gets the job done without creating a backlog.
Myricetin's mechanism operates through multiple parallel pathways without COMT interaction:
Antioxidant Pathway:
- Direct free radical scavenging via electron donation from hydroxyl groups
- Chelation of Fe²⁺ and Cu²⁺ ions preventing Fenton reaction: Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻
- Upregulates antioxidant defense by activating Nrf2 (nuclear factor erythroid 2-related factor 2)
- Nrf2 translocates to nucleus → binds antioxidant response element (ARE) → transcribes SOD, catalase, glutathione peroxidase, glutathione reductase
Anti-inflammatory Cascade:
- Inhibits IκB kinase (IKK) → blocks phosphorylation of IκB → prevents IκB degradation → NF-κB remains sequestered in cytoplasm (cannot translocate to nucleus)
- Without nuclear NF-κB: reduced transcription of TNF-α, IL-1β, IL-6, COX-2, iNOS
- Direct COX-2 enzyme inhibition (competitive binding at active site) → reduced prostaglandin E2 (PGE2) synthesis from arachidonic acid
- Inhibits LOX pathways (5-LOX, 12-LOX, 15-LOX) → reduced leukotriene B4 and other pro-inflammatory eicosanoids
COMT Non-Interaction (structural basis):
- Catechol structure = two adjacent hydroxyl groups on benzene ring (ortho-dihydroxy)
- COMT specifically methylates catechol structures: catechol + SAM (S-adenosylmethionine) → methylated catechol + SAH (S-adenosylhomocysteine)
- Myricetin lacks this ortho-dihydroxy arrangement → COMT enzyme does not recognize it → no methylation → no accumulation in slow COMT metabolizers
graph TD
A[Myricetin Ingestion] --> B[Intestinal Absorption]
B --> C1[Antioxidant Activity]
B --> C2[Anti-Inflammatory Activity]
B --> C3[NO COMT Interaction]
C1 --> D1[Free Radical Scavenging]
C1 --> D2["Metal Chelation Fe²⁺/Cu²⁺"]
C1 --> D3[Nrf2 Activation]
D3 --> E1[ARE Transcription]
E1 --> F1["↑SOD ↑Catalase ↑GPx"]
C2 --> D4[IKK Inhibition]
C2 --> D5[COX-2 Inhibition]
D4 --> E2["NF-κB Sequestration"]
E2 --> F2["↓TNF-α ↓IL-6 ↓IL-1β"]
D5 --> F3["↓PGE2 ↓Inflammation"]
C3 --> D6[Lacks Catechol Structure]
D6 --> E3[COMT Enzyme Bypass]
E3 --> F4[Safe in Met/Met Genotype]
Myricetin is a cornerstone intervention for patients with Met/Met COMT genotype (approximately 25% of Caucasian populations, variable in other ethnicities) who require anti-inflammatory and antioxidant support without risk of catechol accumulation. Women with Met/Met genotype face compounded risk due to baseline 30% lower COMT activity and estrogen fluctuations that further inhibit COMT during luteal phase, making myricetin particularly valuable in hormonal dysregulation contexts (PCOS, perimenopause, PMS).
Metamodel Integration:
- Metamodel 0 (Evolution): Myricetin represents dietary resilience strategy — plant diversity providing multiple chemical solutions to oxidative stress independent of host genetic variation
- Metamodel 1 (Low-Grade Inflammation): COX-2 and NF-κB inhibition directly addresses metaflammation without accumulation risk in genetically vulnerable populations
- Selfish Brain/Immune: Provides immune resolution support without triggering catecholamine-based stress responses that catechol compounds can exacerbate in slow COMT metabolizers
Clinical Applications:
- Neuroinflammatory conditions in Met/Met patients (brain fog, migraine, anxiety with inflammatory component)
- Cardiovascular protection (COX-2 inhibition, reduced oxidative LDL modification) without NSAID risks
- Inflammatory bowel disease, rheumatoid arthritis, autoimmune conditions where quercetin contraindicated
- Neuroprotection in neurodegenerative risk (Alzheimer's, Parkinson's) — crosses blood-brain barrier
- Post-viral inflammation (Long-COVID) in COMT-compromised individuals
Dosing Considerations:
- Typical supplemental doses: 100-500 mg daily
- Food sources: bilberries (highest), cranberries, grapes, walnuts, green tea, parsley
- Bioavailability enhanced with piperine, quercetin-free bioflavonoid complexes
Intervention Strategy:
COMT genotyping (or clinical suspicion based on anxiety/stimulant sensitivity) → avoid catechol flavonoids (quercetin, EGCG, luteolin) → substitute with myricetin, apigenin, chrysin, baicalein for anti-inflammatory/antioxidant needs → monitor symptom resolution without catechol-related adverse effects (anxiety escalation, insomnia, digestive upset)
- Myricetin is a flavonol with hydroxyl groups at positions 3, 3', 4', 5, 5', and 7 but lacks the critical catechol (ortho-dihydroxy) structure that makes quercetin a COMT substrate
- Inhibits COX-2 with IC50 ~5-20 μM (comparable to selective NSAIDs in vitro)
- Reduces TNF-α secretion by 40-60% and IL-6 by 30-50% in stimulated macrophage models
- Chelates iron and copper ions preventing hydroxyl radical formation via Fenton chemistry
- Activates Nrf2 pathway increasing cellular glutathione by 20-40% in oxidative stress models
- Food sources include bilberries (180 mg/100g), cranberries (70 mg/100g), walnuts, grapes, kale
- Crosses blood-brain barrier making it relevant for neurodegenerative protection
- Safe for long-term use in Met/Met COMT genotype patients who constitute ~25% of Caucasian populations
- Synergizes with other non-catechol flavonoids (apigenin, chrysin, baicalein) for broader inflammatory modulation
- No documented adverse effects at doses up to 500 mg/day in human trials
- COMT — myricetin lacks catechol structure and therefore bypasses COMT methylation entirely
- catechol-O-methyltransferase — structural absence of ortho-dihydroxy groups prevents enzyme recognition
- quercetin — structural analogue but quercetin contains catechol B-ring and IS methylated by COMT
- EGCG — green tea catechin with catechol structure that inhibits COMT unlike myricetin
- apigenin — fellow non-catechol flavone safe for COMT-compromised patients
- chrysin — non-catechol flavone alternative with anti-inflammatory properties
- baicalein — non-catechol flavone from Scutellaria providing complementary pathway modulation
- genistein — isoflavone lacking catechol structure suitable for slow COMT metabolizers
- NF-κB — myricetin inhibits IKK preventing nuclear translocation and inflammatory gene transcription
- Nrf2 — activated by myricetin leading to antioxidant response element transcription
- COX-2 — directly inhibited by myricetin reducing prostaglandin E2 synthesis
- TNF-α — production reduced 40-60% via NF-κB pathway inhibition
- IL-6 — decreased 30-50% through transcriptional suppression
- oxidative stress — scavenged by myricetin's multiple hydroxyl groups and metal chelation
- inflammation — multiple pathway inhibition (COX-2, LOX, NF-κB) provides broad anti-inflammatory action
- anxiety — safe anti-inflammatory option when catechol flavonoids exacerbate anxiety in Met/Met COMT
- low-grade inflammation — addresses metaflammation without COMT interaction concerns
- polyphenols — member of flavonol subclass providing antioxidant and anti-inflammatory effects
- flavonoids — flavonol structure with unique non-catechol advantage for genetic vulnerability
- 5-HTTLPR — both COMT Met/Met and short 5-HTTLPR alleles increase stress sensitivity; myricetin addresses inflammation without worsening catecholamine dysregulation
- estrogen — estrogen inhibits COMT making myricetin particularly important for women with slow COMT genotype
- SAM-e — COMT uses SAM as methyl donor; myricetin preserves SAM pools in slow metabolizers by not consuming it
- glutathione — upregulated 20-40% via Nrf2 activation enhancing cellular antioxidant capacity
- Module 2 — Evolutionary Medicine (COMT genetic variation, flavonoid diversity as evolutionary adaptation)
- Module 8 — Nutrition & Immunonutrition (polyphenol mechanisms, COMT-flavonoid interactions)